Payment overview · 2025
General Payments
$457.81
24 reported records · 14 companies
Healthcare provider profile · identity verified
Jonathan Lance Underwood, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VALDOSTA, GA · NPI 1265612972
Verified facts
What the public records show
CMS Open Payments records show Jonathan Lance Underwood, MD received $457.81 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.82 | 15.0% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $52.59 | 11.5% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $40.48 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.19 | 7.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.05 | 7.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $32.33 | 7.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.26 | 7.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.85 | 7.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.99 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.34 | 5.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.08 | 5.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.07 | 5.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.20 | 3.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.56 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $457.81 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $57.84 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $52.59 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $40.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 202 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
202 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 21 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 733 | 180 |
| Losartan Potassium | Losartan Potassium | 606 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 598 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 495 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 124 |
| Tramadol Hcl | Tramadol Hcl | 405 | 96 |
| Potassium Chloride | Potassium Chloride | 400 | 119 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 380 | 123 |
| Metformin Hcl | Metformin Hcl | 375 | 107 |
| Gabapentin | Gabapentin | 336 | 89 |
| Lisinopril | Lisinopril | 332 | 79 |
| Alprazolam | Alprazolam | 322 | 70 |
| Montelukast Sodium | Montelukast Sodium | 322 | 85 |
| Meloxicam | Meloxicam | 320 | 101 |
| Simvastatin | Simvastatin | 298 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 294 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 274 | 58 |
| Sertraline Hcl | Sertraline Hcl | 274 | 67 |
| Omeprazole | Omeprazole | 257 | 71 |
| Famotidine | Famotidine | 247 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 66 |
| Ezetimibe | Ezetimibe | 245 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 229 | 53 |
| Furosemide | Furosemide | 227 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 58 |
| Ozempic | Semaglutide | 202 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 102 |
| Azithromycin | Azithromycin | 188 | 146 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 43 |
| Glimepiride | Glimepiride | 186 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 167 | 39 |
| Trazodone Hcl | Trazodone Hcl | 161 | 52 |
| Felodipine Er | Felodipine | 149 | 41 |
| Januvia | Sitagliptin Phosphate | 144 | 46 |
| Carvedilol | Carvedilol | 134 | 29 |
| Donepezil Hcl | Donepezil Hcl | 131 | 29 |
| Methylprednisolone | Methylprednisolone | 126 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 112 | 83 |
| Allopurinol | Allopurinol | 107 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 87 |
| Valsartan | Valsartan | 104 | 26 |
| Alendronate Sodium | Alendronate Sodium | 100 | 24 |
| Fluconazole | Fluconazole | 100 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 22 |
| Clonidine Hcl | Clonidine Hcl | 96 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 23 |
| Mounjaro | Tirzepatide | 82 | 16 |
| Atenolol | Atenolol | 78 | 22 |
| Trulicity | Dulaglutide | 78 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 22 |
| Eliquis | Apixaban | 66 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 13 |
| Bupropion Xl | Bupropion Hcl | 61 | 14 |
| Glipizide | Glipizide | 60 | 15 |
| Metformin Hcl Er | Metformin Hcl | 59 | 17 |
| Myrbetriq | Mirabegron | 59 | 12 |
| Pregabalin | Pregabalin | 59 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 47 |
| Farxiga | Dapagliflozin Propanediol | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 45 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Linzess | Linaclotide | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 40 |
| Ondansetron Odt | Ondansetron | 50 | 33 |
| Sucralfate | Sucralfate | 49 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | suppressed |
| Celecoxib | Celecoxib | 48 | 13 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 19 |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 21 |
| Jardiance | Empagliflozin | 42 | 12 |
| Temazepam | Temazepam | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 15 |
| Fenofibrate | Fenofibrate | 35 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 12 |
| Mometasone Furoate | Mometasone Furoate | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 13 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 20 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Constulose | Lactulose | 20 | suppressed |
| Lactulose | Lactulose | 20 | 13 |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $457.81 · 24 records | PFIZER INC. | ABRYSVO, ACCRUFER, Auvelity, COMIRNATY, Flector, Fluad, Flucelvax, Leqembi, Licart, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, Tirosint, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error